Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18754049 | NONIONIC POLYETHER SURFACTANTS | June 2024 | June 2025 | Allow | 11 | 1 | 0 | No | No |
| 18636731 | AMINOPYRIMIDINE/PYRAZINE DERIVATIVES AS CTPS1 INHIBITORS | April 2024 | February 2025 | Allow | 10 | 0 | 0 | No | No |
| 18598033 | METHOD FOR SEPARATING FLAVOKAWAIN AND KAVALACTONE, KAVALACTONE, AND MICROENCAPSULATED KAVALACTONE | March 2024 | September 2024 | Allow | 6 | 1 | 0 | No | No |
| 18392193 | SUBLINGUAL PHENTERMINE SPRAY COMPOSITIONS AND DAY-NIGHT APPETITE SUPPRESSION AND WEIGHT LOSS REGIMEN USING SAME | December 2023 | March 2025 | Allow | 15 | 1 | 0 | No | No |
| 18368099 | CRYSTALLINE HYDROCHLORIDE SALTS OF N-ETHYL-2-(5-FLUORO-1H-INDOL-3-YL)-N-METHYLETHAN-1-AMINE | September 2023 | August 2024 | Allow | 11 | 2 | 1 | No | No |
| 18180181 | CDK Inhibitors And Their Use As Pharmaceuticals | March 2023 | May 2025 | Abandon | 26 | 1 | 1 | No | No |
| 18172656 | POLYMORPHS OF A DIHYDROOROTATE DEHYDROGENASE (DHOD) INHIBITOR | February 2023 | April 2024 | Allow | 14 | 1 | 1 | Yes | No |
| 18171822 | SUBLINGUAL PHENTERMINE SPRAY COMPOSITIONS AND DAY-NIGHT APPETITE SUPPRESSION AND WEIGHT LOSS REGIMEN USING SAME | February 2023 | March 2025 | Allow | 24 | 4 | 2 | Yes | No |
| 18106290 | METHODS FOR THE TREATMENT OF LYSOSOMAL STORAGE DISEASES | February 2023 | March 2024 | Allow | 13 | 1 | 0 | Yes | No |
| 18164286 | METHODS OF SYNTHESIZING DEUTERATED SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS | February 2023 | August 2024 | Abandon | 19 | 2 | 0 | Yes | No |
| 18161402 | Scalp Numbing System | January 2023 | August 2024 | Abandon | 19 | 2 | 1 | No | No |
| 18099291 | PHARMACEUTICAL COMPOSITION FOR TREATING LOCALLY ADVANCED MISMATCH REPAIR-PROFICIENT/MICROSATELLITE STABLE (PMMR/MSS) COLORECTAL CANCER (CRC) AND USE THEREOF | January 2023 | June 2024 | Allow | 17 | 1 | 1 | No | No |
| 18154349 | TOFACITINIB-CONTAINING ANHYDROUS ELASTOMER-BASED GEL FORMULATIONS | January 2023 | May 2024 | Abandon | 16 | 1 | 0 | No | No |
| 17990321 | Drug delivery via contact lenses and similar ophthalmic devices | November 2022 | April 2024 | Abandon | 17 | 1 | 0 | Yes | No |
| 18047497 | BACTERIAL NITRIC OXIDE SYNTHASE INHIBITORS | October 2022 | September 2024 | Allow | 23 | 1 | 1 | No | No |
| 17936508 | PARATHYROID HORMONE (PTH) RECEPTOR ANTAGONISTS AND USES THEREOF | September 2022 | January 2024 | Abandon | 16 | 0 | 1 | No | No |
| 17906367 | COCRYSTALS OF (1R,3S)-3-(5-CYANO-4-PHENYL-1,3-THIAZOL-2-YLCARBAMOYL)CYCLOPENTANE CARBOXYLIC ACID | September 2022 | May 2025 | Allow | 32 | 0 | 0 | No | No |
| 17941611 | INHIBITORS OF C. DIFFICILE SPORE GERMINATION | September 2022 | June 2024 | Allow | 22 | 2 | 1 | No | No |
| 17821314 | METHODS OF IRON CATALYZED C-H BOND AMINATION | August 2022 | May 2024 | Allow | 21 | 1 | 1 | Yes | No |
| 17866227 | IL-17 LIGANDS AND USES THEREOF | July 2022 | August 2024 | Allow | 25 | 1 | 1 | Yes | No |
| 17724724 | COMPOUNDS AS LXR AGONISTS | April 2022 | June 2024 | Abandon | 26 | 0 | 1 | No | No |
| 17622608 | PROMOTING TISSUE REGENERATION | December 2021 | May 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17622042 | ARTEMISININ-DERIVATIVE N-HETEROCYCLIC CARBENE GOLD(I) HYBRID COMPLEXES | December 2021 | December 2024 | Allow | 36 | 0 | 0 | Yes | No |
| 17557567 | COMBINATION THERAPY WITH A PHOSPHOINOSITIDE 3-KINASE INHIBITOR WITH A ZINC BINDING MOIETY | December 2021 | May 2025 | Allow | 40 | 1 | 1 | No | No |
| 17617711 | ANTIBIOTIC POTENTIATION FOR NONTUBERCULOUS MYCOBACTERIAL DISEASE | December 2021 | May 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17456033 | CANNABINOL-O-ACETATE SYNTHESIS, COMPOSITIONS, AND METHODS OF USE | November 2021 | February 2024 | Abandon | 27 | 0 | 1 | No | No |
| 17609021 | PRODRUG COMPOUNDS | November 2021 | May 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17499248 | RESIQUIMOD TOPICAL AND INJECTABLE COMPOSITIONS FOR THE TREATMENT OF NEOPLASTIC SKIN CONDITIONS | October 2021 | April 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17492320 | ISOPROPYLCARBONATE BENZOYL PEROXIDE COMPOSITIONS AND METHODS OF USE | October 2021 | March 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17442285 | SALTS OF 5,6-DIHYDRO-4H-THIENO[2,3-C]PYRROL-4-ONE COMPOUND AS ERK INHIBITORS | September 2021 | April 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17436885 | SMALL MOLECULE MODULATORS OF IL-17 | September 2021 | August 2024 | Allow | 36 | 0 | 0 | Yes | No |
| 17436884 | COMPOSITIONS FOR PATHOGEN INACTIVATION OR PATHOGEN REDUCTION MANAGEMENT | September 2021 | March 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17433193 | 2-HETEROARYL AMINOQUINAZOLINONE DERIVATIVE | August 2021 | May 2025 | Allow | 45 | 2 | 1 | No | No |
| 17432485 | TREATMENT FOR RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR V (RORV) -DEPENDENT CANCERS | August 2021 | January 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17430219 | PHARMACEUTICAL COMBINATION COMPRISING TNO155 AND RIBOCICLIB | August 2021 | February 2025 | Allow | 42 | 1 | 0 | Yes | No |
| 17310268 | 15-PGDH INHIBITORS | July 2021 | November 2024 | Allow | 40 | 1 | 1 | Yes | No |
| 17423778 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | July 2021 | December 2024 | Abandon | 41 | 0 | 1 | No | No |
| 17374509 | NONIONIC POLYETHER SURFACTANTS | July 2021 | October 2024 | Abandon | 39 | 3 | 1 | No | No |
| 17422283 | NLRP3 MODULATORS | July 2021 | August 2024 | Allow | 37 | 1 | 1 | Yes | No |
| 17418323 | DIKETOPIPERAZINE DERIVATIVES AS CALCIUM ATPASE INHIBITOR FOR ENHANCING ANTICANCER ACTIVITY | June 2021 | August 2024 | Allow | 38 | 1 | 0 | No | No |
| 17350581 | Compounds, Compositions and Methods | June 2021 | August 2024 | Allow | 38 | 0 | 1 | No | No |
| 17349862 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | June 2021 | September 2024 | Abandon | 39 | 0 | 1 | No | No |
| 17345688 | COMPOUNDS AND COMPOSITIONS THAT CAUSE MYCN AND/OR CMYC DEGRADATION AND METHODS OF USE THEREOF | June 2021 | December 2024 | Abandon | 42 | 0 | 1 | No | No |
| 17413406 | PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF CIRCADIAN RHYTHM-RELATED DISORDERS, COMPRISING OXYIMINOMETHYLBENZENE DERIVATIVE AS ACTIVE INGREDIENT | June 2021 | December 2024 | Allow | 42 | 2 | 0 | No | No |
| 17312858 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | June 2021 | May 2024 | Allow | 35 | 2 | 1 | No | No |
| 17312077 | Aqueous Based Pharmaceutical Formulations of 1,2-Dihydropyridine Compounds | June 2021 | January 2025 | Allow | 43 | 1 | 1 | Yes | No |
| 17312196 | SALIVARY GLAND REGENERATION | June 2021 | January 2025 | Allow | 44 | 1 | 1 | No | No |
| 17255707 | PHARMACEUTICAL COMPOSITION CONTAINING 9-ETHYL-6, 6-DIMETHYL-8-(4-MORPHOLIN-4-YL-PIPERIDIN-1-YL)-11-OXO-6, 11-DIHYDRO-5H-BENZO[B]CARBAZOLE-3-CARBONITRILE | June 2021 | August 2024 | Allow | 43 | 3 | 0 | Yes | No |
| 17311105 | TYROSINE KINASE INHIBITORS, COMPOSITIONS AND METHODS THERE OF | June 2021 | October 2024 | Abandon | 40 | 0 | 1 | No | No |
| 17299741 | METHODS OF TREATING CONDITIONS RELATED TO THE S1P1 RECEPTOR | June 2021 | June 2025 | Abandon | 48 | 2 | 1 | No | No |
| 17299696 | (PYRIDIN-2-YL)AMINE DERIVATIVES AS TGF-BETA R1 (ALK5) INHIBITORS FOR THE TREATMENT OF CANCER | June 2021 | June 2024 | Allow | 36 | 1 | 1 | No | No |
| 17299634 | CYCLOBUTYL PYRAZOLOPYRIMIDINE PDE9 INHIBITORS | June 2021 | November 2024 | Allow | 42 | 2 | 0 | No | No |
| 17299733 | SMALL MOLECULE INHIBITION OF SULFOTRANSFERASE SULT1A3 | June 2021 | February 2025 | Allow | 45 | 2 | 1 | Yes | No |
| 17295327 | METHODS OF TREATING CANCERS | May 2021 | April 2025 | Abandon | 47 | 2 | 1 | No | No |
| 17293157 | HETEROCYCLIC SPIRO-COMPOUNDS AS AM2 RECEPTOR INHIBITORS | May 2021 | September 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17306167 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | May 2021 | December 2024 | Allow | 43 | 2 | 0 | No | No |
| 17288718 | DRUG FOR TREATING TINNITUS | April 2021 | November 2024 | Allow | 43 | 1 | 1 | No | No |
| 17287137 | Aminopyrimidine/pyrazine derivatives as CTPS1 inhibitors | April 2021 | March 2024 | Allow | 35 | 1 | 0 | No | No |
| 17286002 | DEUTERATED MELFLUFEN COMPOUNDS | April 2021 | July 2024 | Allow | 39 | 1 | 1 | Yes | No |
| 17224902 | ADDICTION TREATMENT OF AN ALCOHOL-CONSUMING PATIENT POPULATION | April 2021 | May 2025 | Abandon | 49 | 2 | 1 | No | No |
| 17281525 | INDOLE MACROCYCLIC DERIVATIVE, PREPARATION METHOD THEREOF AND APPLICATION THEREOF IN MEDICINE | March 2021 | July 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17280245 | PYRAZOLOPYRIMIDINE COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF IN PREPARATION OF ANTI-CANCER DRUG | March 2021 | April 2024 | Allow | 37 | 1 | 0 | Yes | No |
| 17279765 | METHODS OF TREATING MYELOPROLIFERATIVE DISORDERS | March 2021 | June 2025 | Abandon | 51 | 3 | 0 | No | No |
| 17278397 | NOVEL QUINAZOLINE EGFR INHIBITORS | March 2021 | July 2024 | Abandon | 39 | 0 | 1 | No | No |
| 17277759 | COMPOSITIONS AND METHODS FOR INHIBITING ACSS2 | March 2021 | November 2024 | Abandon | 43 | 1 | 1 | No | No |
| 17277706 | COMPOSITION FOR INHIBITION OR TREATMENT OF BRAIN TUMORS OR SYMPTOMS ATTRIBUTABLE THERETO | March 2021 | July 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17275918 | COMPOSITIONS AND METHODS FOR ENHANCING WOUND HEALING | March 2021 | June 2024 | Abandon | 39 | 1 | 0 | No | No |
| 17195624 | COMPOUND, PREPARATION METHOD AND USE THEREOF | March 2021 | December 2023 | Allow | 33 | 1 | 0 | Yes | No |
| 17182375 | 6-AMINOPYRIDIN-3-YL THIAZOLES AS MODULATORS OF RORyT | February 2021 | May 2024 | Abandon | 39 | 0 | 1 | No | No |
| 17267439 | SUBSTITUTED BISPHENYLALKYLUREA COMPOUNDS AND METHODS OF TREATING BREAST CANCER | February 2021 | February 2025 | Allow | 48 | 2 | 1 | No | No |
| 17164045 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY | February 2021 | April 2024 | Allow | 38 | 1 | 0 | No | No |
| 17264684 | BICYCLIC HETEROARYL DERIVATIVES AS ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1 INHIBITORS | January 2021 | April 2024 | Allow | 39 | 2 | 1 | No | No |
| 17263164 | MEDICINAL PRODUCT, ANTICANCER AGENT, MEDICINAL INTERMEDIATE PRODUCT, AND METHOD FOR PRODUCING CYCLIC CARBOXYLIC ACID COMPOUND OR DERIVATIVE THEREOF | January 2021 | March 2024 | Abandon | 38 | 0 | 1 | No | No |
| 17262452 | TRIPLET-TRIPLET ENERGY TRANSFER WITH LIGHT EXCITATION AT LONG WAVELENGTHS AND METHODS THEREOF | January 2021 | April 2024 | Allow | 39 | 2 | 0 | No | No |
| 17104770 | METHODS FOR IMPROVING PURITY OF TENOFOVIR DISOPROXIL FUMARATE, AND COMPOSITIONS THEREOF | November 2020 | April 2024 | Abandon | 41 | 0 | 1 | No | No |
| 17081291 | STABLE PHARMACEUTICAL COMPOSITIONS | October 2020 | July 2024 | Abandon | 45 | 1 | 1 | No | No |
| 17046663 | CONVERSION OF 1,2,5,6-HEXANETETROL (HTO) TO TETRAHYDROFURAN dicarboxylic acid (THFDCA) | October 2020 | January 2024 | Allow | 40 | 1 | 0 | No | No |
| 17043017 | PROCESS FOR MAKING SARECYCLINE HYDROCHLORIDE | September 2020 | August 2024 | Allow | 47 | 2 | 0 | No | No |
| 16904358 | COMPOSITIONS AND METHODS FOR DIAGNOSING URINARY TRACT INFECTIONS | June 2020 | July 2024 | Abandon | 49 | 2 | 0 | No | No |
No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.
Examiner NOTTINGHAM, KYLE GREGORY works in Art Unit 1621 and has examined 76 patent applications in our dataset. With an allowance rate of 52.6%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 39 months.
Examiner NOTTINGHAM, KYLE GREGORY's allowance rate of 52.6% places them in the 9% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by NOTTINGHAM, KYLE GREGORY receive 1.09 office actions before reaching final disposition. This places the examiner in the 16% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by NOTTINGHAM, KYLE GREGORY is 39 months. This places the examiner in the 9% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +47.5% benefit to allowance rate for applications examined by NOTTINGHAM, KYLE GREGORY. This interview benefit is in the 93% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 33.3% of applications are subsequently allowed. This success rate is in the 65% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 72.7% of cases where such amendments are filed. This entry rate is in the 92% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants file petitions regarding this examiner's actions, 66.7% are granted (fully or in part). This grant rate is in the 82% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 0% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 10.0% of allowed cases (in the 88% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.